PTGS1 and melanoma: Most mice that rejected Ptgs1/Ptgs2−/− cells were resistant to a subsequent challenge with unmodified parental BrafV600E melanoma cells (Figure 4D), implying the development of immunity to shared target antigens and excluding a scenario of cancer immune privilege driven locally by tumor-derived prostanoids.